Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × Sorafenib × Clear all

NCT00526799 2016-03-03

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Phase 1/2 Terminated

30 enrolled 16 charts

Ovarian Neoplasms